BOSTON–Nuclera and researchers at the University of Cambridge have demonstrated a new approach to producing and analyzing complex proteins involved in drug development, potentially reducing the time required for structural biology research.
The biotechnology company announced findings from a collaboration with the University of Cambridge’s Department of Biochemistry that combined cell-free protein synthesis, specialized nanodisc technology, and cryo-electron microscopy (cryo-EM) to examine a challenging class of proteins known as G protein-coupled receptors (GPCRs).
The research, published as a preprint on bioRxiv, describes how scientists obtained a high-resolution structure of an engineered human adenosine A2A receptor bound to an antagonist, completing the process from gene assembly to cryo-EM sample preparation in just four days.
The researchers achieved a structural resolution of 3.38 angstroms, allowing them to examine the receptor’s molecular architecture in detail.
GPCRs are an important class of proteins involved in transmitting signals between cells and are widely studied as potential targets for pharmaceutical treatments.
However, producing sufficient quantities of stable, properly folded GPCRs for structural analysis has historically been difficult, often requiring lengthy optimization and purification procedures.
To address these challenges, the researchers combined Nuclera’s protein discovery system with the University of Cambridge’s expertise in cryo-electron microscopy.
Using cell-free protein synthesis, the team evaluated different versions of the adenosine A2A receptor under six lipid nanodisc conditions from Nuclera’s GPCR nanodisc panel.
The researchers selected one of the conditions that produced the highest protein yields and expanded production for purification, quality assessment, and structural analysis.
The resulting samples enabled scientists to obtain a high-resolution image of the receptor bound to an antagonist. The protein’s structure closely matched that of a reference receptor produced using conventional methods.
The team also examined whether the approach could be applied to other difficult-to-produce proteins.
Researchers successfully produced and purified 12 additional GPCRs across Classes A, B, and C, including six orphan receptors whose naturally occurring activating molecules have not yet been identified.
These proteins were evaluated using fluorescence-detection size-exclusion chromatography, a technique used to assess protein quality and stability.
The results suggest the approach could support further structural and biophysical research involving a wider range of therapeutic targets.
“Advances in cryo-EM have transformed our ability to investigate protein structures, but obtaining suitable samples remains a major challenge, particularly for complex membrane proteins. This research demonstrates that rapid, cell-free protein production can deliver high-quality, active protein suitable for high-resolution structural analysis, potentially opening up opportunities to investigate a wider range of challenging drug targets,” said Dr. Dimitri Chirgadze, Cryo-EM Facility Manager in the Department of Biochemistry at the University of Cambridge.
Structural biology plays an important role in modern drug discovery by allowing researchers to examine the three-dimensional shapes of proteins and identify how potential drug molecules interact with them.
Faster access to reliable protein samples could help researchers investigate new therapeutic targets and support the design of treatments for diseases involving complex cellular signaling pathways.
“Access to membrane proteins remains a significant obstacle in drug discovery. By combining our cell-free protein synthesis and proprietary nanodisc technology with the University of Cambridge’s structural biology expertise, we have demonstrated a faster route to producing proteins suitable for high-resolution analysis. This represents an important step towards making difficult-to-study drug targets more accessible, with the potential to accelerate structural biology research and streamline future drug discovery,” said Dr. Michael Chen, Co-Founder and Chief Scientific and Business Officer at Nuclera.
The findings remain preliminary because the research was published as a preprint and has not yet undergone peer review.
The collaboration highlights the potential for integrating advanced protein production technologies with structural imaging techniques to accelerate early-stage drug discovery and expand research into proteins that have traditionally been difficult to study.


